Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.025 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 0.025 mg - levothyroxine sodium is used for the following indications: hypothyroidism - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression - in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions ), including thyroid nodules (see warnings and precautions ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see warnings and precautions ), and, as an adjunct to surgery and radioiodine therapy in the managem

Stati Uniti - inglese - NLM (National Library of Medicine)

tya pharmaceuticals - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 50 ug - levothyroxine sodium is used for the following indications: – as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.  specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. hypothyroidism – in the treatment or prevention of various types of euthyroid goiters (see and  ), including thyroid nodules (see and  ), subacute or chronic lymphocytic thyroiditis (hashimoto’s thyroiditis), multinodular goiter (see  and  ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Stati Uniti - inglese - NLM (National Library of Medicine)

stat rx usa llc - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium 0.05 mg - levothyroxine sodium is used for the following indications: hypothyroidism - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression - in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions ), including thyroid nodules (see warnings and precautions ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see warnings and precautions ), and, as an adjunct to surgery and radioiodine therapy in the managem

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.15 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.075 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.05 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.